Introduction {#sec1-1}
============

The use of clopidogrel in combination with aspirin is recommended for the prevention of ischemic events in cardiovascular patients with acute coronary syndrome (ACS) or in those undergoing percutaneous coronary intervention (PCI) according to current guidelines ([@ref1]). Despite this standard treatment, there are still numerous adverse cardiovascular events, and attenuated responses to clopidogrel therapy and clopidogrel resistance (CR) are regarded to be the main reasons.

Clopidogrel is an inactive prodrug that is absorbed by regula-ting the P-glycoprotein encoded by ABCB1 gene in the intestine. This requires two bioconversion steps that are regulated by the hepatic cytochrome P450 (CYP) system to form active product, which targets and blocks adenosine diphosphate (ADP) P2Y12 receptor, and indirectly inhibits GPIIb/IIIa receptor-binding fib-rinogen, and then inhibits platelet aggregation ([@ref2]).

Although the mechanism of CR has not been fully elucidated yet, a variety of factors, including external and internal factors, have been identified. External factors included patient compliance, drug dose, and drug interactions. Internal factors inclu-ded gene polymorphisms, activation of other platelet pathways, and increased release of ADP. Among these factors, hepatic cytochrome P4502C19 (CYP2C19) is one of the key enzymes of clopidogrel oxidative metabolism, which plays a role as the main metabolic enzyme of the CYP system. The main mutant alleles, CYP2C19\*2 and CYP2C19\*3, are the most common genotypes in Asian populations (frequency of 30%--50% and 5%--10%, respectively) ([@ref3]). The presence of CYP2C19\*2 or CYP2C19\*3 mutant allele increases CR risk ([@ref4],[@ref5]). The other two alleles, CYP2C19\*4 and CYP2C19\*5, are mainly distributed in Caucasian race and are associated with attenuated response to clopidogrel. Although platelet aggregation significantly decreases in patients with CYP2C19\*17 mutant allele, the risk of ischemic events significantly increases ([@ref6]). ABCB1 is a family of transmembrane transporters that primarily transport substrates to the plasma membrane u-sing the energy generated by ATP hydrolysis. It plays a leading role in the human multiple drug resistance gene family, the mutation influences the absorption of clopidogrel, but the correlation with CR has not reached a consensus.

Therefore, this study aimed to investigate the association between CYP2C19 and ABCB1 polymorphisms and CR risk in clopidogrel-treated Chinese patients to provide evidence for the early prediction of CR, to guide the rational use of drugs, and to reduce the incidence of adverse cardiovascular events.

Methods {#sec1-2}
=======

Study populations {#sec2-1}
-----------------

The patients were selected from May to October 2016. A total of 325 patients were enrolled in the study, including 101 experimental group patients and 224 control group patients. The exclusion criteria of the experimental group were as follows: ([@ref1]) Patients with cardiovascular disease, including ACS and undergoing PCI; and ([@ref2]) Consecutive clopidogrel on-treatment patients, including imported drugs, such as Plavix (a loading dose of 300 mg for first time, followed by 75 mg/day), and domestic drug, such as Taijia (50 mg/day), with platelet function testing. The exclusion criteria of the control group were as follows: The chest X-ray, physical examination, electrocardiogram, blood routine parameters, urine routine parameters, blood biochemical tests, medical history were no abnormalities, no chronic bleeding and bleeding tendency, coagulation index and platelet aggregation rate without exception. The study protocol complied with the Declaration of Helsinki and was approved by the Ethics Committee.

CYP2C19 genotyping by time-of-flight mass spectrometry (Clin-TOF) and Sanger sequencing {#sec2-2}
---------------------------------------------------------------------------------------

Genomic DNA was extracted from blood using the Blood genomic DNA Extraction Kit \[DP348, Tiangen Biotech (Beijing) Co., Ltd.\]. Primers were designed by Bioyong Technologies Inc., and synthesized by Generay Biotech (Shanghai) Co., Ltd. First, multiplex PCR reactions were performed with 5 µL of reaction mixture, comprising 1 µL genomic DNA, 2.78 µL PCR mixture I, 0.22 µL enzyme I, and 1 µL amplification primer. The PCR conditions were as follows: initial denaturation at 37°C for 10 min and 95°C for 10 min; 45 cycles of annealing at 95°C for 30 s, 56°C for 30 s, and 72°C for 60 s; and final extension at 72°C for 5 min. Then, SAP was used to eliminate uncombined dNTPs after amplification in order to make them unavailable for future reaction. Dephosphorylation conditions were 37°C for 40 min and 85°C for 5 min. Finally, single-base primer extension reactions were conducted using the following reaction mixture: 1.019 µL PCR mixture III, 0.041 µL enzyme III, and 0.940 µL amplification primer. The reactions were performed using a two-cycling loop program as follows: initial denaturation at 94°C for 30 s; 40 cycles of annealing at 94°C for 5 s, 56°C for 5 s, and 80°C for 5 s; and final extension at 72°C for 3 min. These annealing and extension steps were repeated five times.

Genotypes were determined using time-of-flight mass spectrometry (CLIN-TOF-II, Bioyong Technologies Inc.) and Sanger sequencing at Beijing Sunbiotech Co., Ltd.

The primer sequences used in DNA sequencing are as follows: CYP2C19\*2-F: AACCAGAGCTTGGCATATTG; CYP2C19\*2-R: TGCTTCTCAAGCATTACTCC; CYP2C19\*3-F: TTCCAATCATTTAGCTTCACCCT; CYP2C19\*3-R: GCATAAAATAAAGAACTTTGCCATC; CYP2C19\*4-F: TGCATTGGAACCACTTGG; CYP2C19\*4-R: TCCCTTACTGTTTACCCTCA; CYP2C19\*5-F: CCTCCTATGATTCACCGAACAGT; CYP2C19\*5-R: GGGTCAATCAGAGATTTCAGGTTA; CYP2C19\*17-F: ACCAGGAGGTCAAGAAGC; CYP2C19\*17-R: GAAGGCAGGAATTGTTAT; ABCB1-F: TCACAAGGAGGGTCAGG; and ABCB1-R: TTGGCAGTTTCAGTGTAAGA.

Platelet function testing {#sec2-3}
-------------------------

ADP-induced platelet inhibition rate was measured by TEG^®^ 5000 Thrombelastograph^®^ Hemostasis Analyzer system (Haemonetics Corporation). Volume of 2.7 mL venous blood anticoagulation with 3.2% sodium citrate and 4.0 mL venous blood anticoagulation with 14.7 U/mL lithium heparin was collected from patients received clopidogrel (75 mg, once daily) after 4 days, and completed test within 4 h. The analyzer has three channels; 20 µL 0.2 ml/L CaCl~2~ and 340 µL blood anticoagulation with citrate which mixed with Kaolin were added into 1-channel; 10 µL activator F and 360 µL blood anticoagulation with heparin were added into 2-channel; and 10 µL activator F, 10 µL ADP and 360 µL blood anticoagulation with heparin were added into 3-channel. Platelet inhibition rate was calculated by the instrument software, and the results were expressed as a percentage (%).

Clinical data collection {#sec2-4}
------------------------

The demographic characteristics and baseline data, including age; gender; BMI; coronary risk factors (e.g., smoking, hypertension, and diabetes mellitus); and use of other medications \[e.g., angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), and calcium-channel blocker\], of 101 experimental group patients were collected and evaluated. These data were obtained through reviewing medical records of hospital.

Statistical methods {#sec2-5}
-------------------

Data are expressed as number (percentage), mean±SD, or median with interquartile range (IQR). Continuous variables were analyzed using unpaired two-tailed t-test and ANOVA for \>2 groups for Gaussian distribution and nonparametric tests for non-Gaussian distribution. Allele frequencies were analyzed using X^2^ test. The correlation between genotype and ADP-induced platelet inhibition rates was analyzed using Pearson correlation coefficient test. Other potential confounding factors between genotypes and the efficacy of clopidogrel treatment were excluded using multivariate logistic regression analysis. Statistical analyses were performed using the SPSS software, version 19.0 (SPSS, IL, USA). P\<0.05 was considered statistically significant.

Results {#sec1-3}
=======

Study population and CYP2C19\*2 or \*3 genotyping {#sec2-6}
-------------------------------------------------

A cohort of 101 experimental group patients was divided into three groups according to CYP2C19 genotype as follows: wild-type homozygotes (\*1/\*1, n=38), heterozygous (\*1/\*2 or \*1/\*3, n=53), and mutation homozygous (\*2/\*2, \*2/\*3 or \*3/\*3, n=10). Baseline characteristics of the study population according to their CYP2C19 genotype are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Baseline characteristics of the experimental group patients according to the CYP2C19\*2 and \*3 genotype

                                                  CYP2C19       CYP2C19       CYP2C19       *P* (value)
  ----------------------------------------------- ------------- ------------- ------------- -------------
  Age, years                                      69.71±13.44   69.62±11.20   64.30±15.38   0.440
  Male (%)                                        8 (21.1%)     17 (32.1%)    3 (30.0%)     0.512
  BMI^[a](#t1f1){ref-type="table-fn"}^, Kg/m^2^   23.18±7.89    24.52±4.74    22.54±9.48    0.560
  Smoking status                                                                            0.125
   Non-smoker                                     30 (78.9%)    48 (90.6%)    10 (100%)     
   Ex-smoker                                      4 (10.5%)     3 (5.7%)      0 (0%)        
   Habitual smoker                                4 (10.5%)     2 (3.8%)      0 (0%)        
  Hypertension                                    24 (63.2%)    29 (54.7%)    4 (40.0%)     0.402
  Hyperlipidemia                                  4 (10.5%)     10 (18.9%)    3 (30.0%)     0.297
  Diabetes mellitus                               13 (34.2%)    22 (41.5%)    4 (40.0%)     0.782
  ACEI^[b](#t1f2){ref-type="table-fn"}^           19 (50.0%)    20 (37.7%)    4 (40.0%)     0.477
  ARB^[c](#t1f3){ref-type="table-fn"}^            28 (73.7%)    39 (73.6%)    7 (70.0%)     0.935
  Calcium-channel blocker                         25 (65.8%)    36 (67.9%)    7 (70.0%)     0.982
  β-receptor blocker                              30 (78.9%)    46 (86.8%)    8 (80.0%)     0.579
  Statins                                         35 (92.1%)    51 (96.2%)    10 (100.0%)   0.546
  Proton-pump inhibitor                           22 (57.9%)    30 (56.6%)    4 (40.0%)     0.538
  Aspirin                                         10 (26.3%)    13 (24.5%)    3 (30.0%)     0.941

\- body mass index;

\- angiotensin-converting enzyme inhibitor;

\- angiotensin receptor blocker

Multivariate logistic regression analysis was performed to exclude other potential confounding factors between genotypes and the efficacy of clopidogrel treatment.

Demographic characteristics and baseline data between three genotypes of CYP2C19 groups were well balanced

Genotyping results {#sec2-7}
------------------

The genotyping results of the experimental group and the control group are shown in [Table 2](#T2){ref-type="table"} and [Table 3](#T3){ref-type="table"}, respectively. There was no significant difference between the two groups (p=0.545).

###### 

Genotype frequency of the experimental group

  ------------------------------------------------------------------------------
  Percentage (%)\   Wild-type homozygotes   Genotype\      Mutation homozygous
  Gene                                      Heterozygous   
  ----------------- ----------------------- -------------- ---------------------
  CYP2C19\*2        45 (44.45)              49 (48.51)     7 (6.93)

  CYP2C19\*3        91 (90.10)              10 (9.90)      0

  CYP2C19\*4        101 (100.00)            0              0

  CYP2C19\*5        101 (100.00)            0              0

  CYP2C19\*17       100 (99.01)             1 (0.99)       0

  ABCB1             39 (38.61)              50 (49.50)     12 (11.88)
  ------------------------------------------------------------------------------

###### 

Genotype frequency of the control group

  ------------------------------------------------------------------------------
  Percentage (%)\   Wild-type homozygotes   Genotype\      Mutation homozygous
  Gene                                      Heterozygous   
  ----------------- ----------------------- -------------- ---------------------
  CYP2C19\*2        106 (47.32)             101 (45.09)    17 (7.59)

  CYP2C19\*3        208 (92.86)             16 (7.14)      0

  CYP2C19\*4        223 (99.55)             1 (0.45)       0

  CYP2C19\*5        224 (100.00)            0              0

  CYP2C19\*17       219 (97.77)             5 (2.23)       0

  ABCB1             81 (36.16)              104 (46.43)    39 (17.41)
  ------------------------------------------------------------------------------

Allele frequencies of CYP2C19\*2 and CYP2C19\*3 (A) in the experimental group were 31.19% and 4.95%, respectively. Allele frequencies of CYP2C19\*2 and CYP2C19\*3 (A) in the control group were 30.4% and 4.7%, respectively.

The results of mass spectrometry of the genotype are shown in [Figure 1](#F1){ref-type="fig"}.

![Mass spectrograms for genotypes CYP2C19\*2, CYP2C19\*3, CYP2C19\*4, CYP2C19\*5, CYP2C19\*17, and ABCB1](AJC-19-123-g001){#F1}

Unextend primer (UEP) peak and two different alleles of one genotype are marked by dotted vertical lines in the same color

CYP2C19\*2 or \*3 genotypes and CR {#sec2-8}
----------------------------------

As shown in [Figure 2](#F2){ref-type="fig"}, the median value of ADP-induced platelet inhibition rate in the experimental group was 45.00% (IQR, 27.70%--66.75%). Median ADP-induced platelet inhibition rates among CYP2C19 genotypes were as follows: 57.60% (IQR, 34.78%--74.90%) for wild-type homozygous patients, 39.50% (IQR, 25.65%--62.20%) for heterozygous patients, and 23.45% (IQR, 8.45%--37.65%) for mutant homozygous patients. ADP-induced platelet inhibition rates were significantly different among groups (p=0.013, F=3.355), and the lowest rate was observed for mutant homozygous patients. Moreover, difference in ADP-induced platelet inhibition rates was examined between \*1/\*1, \*1/\*2, \*1/\*3, \*2/\*3, and \*3/\*3; difference between \*1/\*1 and \*1/\*2, \*2/\*2, \*2/\*3 was significant (p=0.30, 0.07, and 0.19, respectively; SD=5.58, 10.48, and 15.27, respectively), but that difference between \*1/\*1 and \*1/\*3 (p=0.563; SD=10.48) was not significant. Multivariate linear regression model revealed that CYP2C19\*2 or \*3 mutant allele was independently associated with ADP-induced platelet inhibition rate (p=0.001; F=11.285; R=0.320^a^).

![CYP2C19\*2 or \*3 genotypes and ADP- induced platelet inhibition rates](AJC-19-123-g002){#F2}

CR risk and presence of CYP2C19\*2 or \*3 genotypes in the experimental group are shown in [Table 4](#T4){ref-type="table"}; there was a statistically significant correlation between the genotypes and CR risk (p=0.028; Pearson Chi-square=7.123), and CR risk was the highest in mutant homozygous patients. Presence of CYP2C19\*2 or \*3 mutant alleles was identified to be an independent predictor of CR risk (p=0.026; t=2.270).

###### 

The relationship between CYP2C19\*2 or \*3 genotypes and CR

  Metabolizes                       Number   Percentage of entire group   Number of CR^[a](#t4f1){ref-type="table-fn"}^   Percentage of CR in entire group
  ----------------------- --------- -------- ---------------------------- ----------------------------------------------- ----------------------------------
  Wild-type homozygotes   \*1/\*1   38       37.62%                       7                                               18.42%
  Heterozygous            \*1/\*2   46       45.54%                       15                                              32.61%
                          \*1/\*3   7        6.93%                        2                                               28.57%
  Total                             53       52.48%                       17                                              32.08%
  Mutation homozygous     \*2/\*2   7        6.93%                        4                                               57.14%
                          \*2/\*3   3        2.97%                        2                                               66.67%
                          \*3/\*3   0        0.00%                        0                                               0.00%
  Total                             10       9.90%                        6                                               60.00%

\- clopidogrel resistance

CYP2C19\*4, CYP2C19\*5, CYP2C19\*17 genotypes {#sec2-9}
---------------------------------------------

Six patients showed CYP2C19\*17 mutant allele; one patient showed CYP2C19\*4 mutant allele; and no patient showed CYP2C19\*5 mutant.

ABCB1 genotypes and CR {#sec2-10}
----------------------

The frequency of ABCB1 mutant allele in the experimental group is shown in [Table 2](#T2){ref-type="table"}. ADP-induced platelet inhibition rates were not significantly different among the groups (p=0.176, F=1.771); this difference between the wild-type homozygous CC and heterozygous TC was significant (p=0.097; SD=5.65), but that between wild-type homozygous CC and mutant homozygous TT (p=0.854; SD=8.73) was not significant. Furthermore, there was no significant correlation between the ABCB1 genotypes and increased CR risk.

Time-of-flight mass spectrometry system technology (Clin-TOF) and Sanger sequencing technology {#sec2-11}
----------------------------------------------------------------------------------------------

Among all 325 patients, 1 patient showed inconsistent sequencing results; the consistency rate between time-of-flight mass spectrometry system (Clin-TOF) and Sanger sequencing was 99.69%; thus, the inconsistency may be due to sample contamination during mass spectrometry.

Discussion {#sec1-4}
==========

Clopidogrel is an oral prodrug that needs to be converted to an active metabolite to irreversibly bind to the P2Y12 receptor. Approximately 85% of clopidogrel is hydrolyzed to inactive metabolites by the contribution of CYP2C19, CYP3A4 or CYP3A5, CYP2C9, CYP1A2, and CYP2B6 isozymes, and the rest passes through two sequential steps that are dependent on cytochrome P450 (CYP) into active metabolites. CYP2C19 genotype affects both metabolic steps and is the most important determinant of the pharmacokinetic and pharmacodynamic responses to clopidogrel although it accounts for only approximately 12% of the reported variability ([@ref7]-[@ref10]). The presence of any dysfunctional CYP2C19 alleles (\*2, \*3, \*4, \*5) is associated with CR risk, ischemic events, and stent thrombosis ([@ref7], [@ref8], [@ref11], [@ref12]), whereas the presence of the CYP2C19 allele (\*17) is associated with an increased risk of bleeding ([@ref13]). Gene mutations that regulate clopidogrel absorption and excretion, such as gene encoding P-glycoprotein multidrug resistance spontaneous transporters, ABCB1 ([@ref14]), may also affect the risk of CR and clinical events during treatment.

In the present study, we observed that the frequencies of CYP2C19\*2 and CYP2C19\*3 alleles (A) in the experimental group and in the control group were consistent with those reported by Zou et al. (30.14% and 3.57%) ([@ref2]) and were higher than those reported in Swedish Caucasians ([@ref15]) and Ethiopians ([@ref16]). The allele frequencies of CYP2C19\*4, CYP2C19\*5, and CYP2C19\*17 in our cohort were lower than those in other races ([@ref17]-[@ref19]), confirming that allelic variants exhibit ethnic and geographic diversity. This study aimed to investigate the association between CYP2C19 and ABCB1 polymorphisms and the antiplatelet effect of clopidogrel. We observed that the presence of CYP2C19\*2 or \*3 mutant allele has a significant effect on platelet function, resulting in significantly lower ADP-induced platelet inhibition rates than in wild-type homozygous. The carriers of CYP2C19\*2 or \*3 mutant allele showed attenuated response to clopidogrel therapy and increased risk of CR. These results are supported by the previous studies ([@ref4]-[@ref6], [@ref20]). ABCB1 mutation resulted in a decreased ADP-induced platelet inhibition in mutant homozygous patients compared to wild-type patients, but there is no evidence regar-ding the association between the ABCB1 genotype and CR. This result was supported by that reported by Shuldiner et al. ([@ref21]) in addition to a significant association between ABCB1 polymorphism and CR reported by other researchers ([@ref22],[@ref23]).

Patients with clinical ACS, particularly those undergoing PCI treatment, are recommended to receive a dual antiplatelet stra-tegy with clopidogrel and aspirin, but the carriage of CYP2C19\*2 or \*3 mutant allele is associated with a higher risk of CR, leading to increased incidence of adverse cardiovascular events. The pharmacogenomic testing of CYP2C19 is recommended by the ACC/AHA guideline to better individualize drug dose for patients to get maximum benefits from an alternative strategy ([@ref24]).

There are a variety of platelet functions testing methods, including platelet aggregation experiments, such as light transmittance aggregometry (LTA), TEG, vasodilator-stimulated phosphoprotein (VASP) phosphorylation method, and use of VerifyNow instrument. LTA has been used as the gold standard; however, this method has a large demand for platelet-rich plasma samples, which is time-consuming and has poor reproducibility. The TEG method is a dynamic depiction of blood coagulation by highly sensitive overhanging filaments, which can provide coagulation and fibrinolytic information as well as a comprehensive reflection of the coagulation cascade reaction and platelet interaction with good reproducibility; thus, we selected TEG to test platelet function in this study.

Currently, there are a variety of methods, including PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) method, use of Taq-Man probes, ARMS (amplification refractory mutation system), genechip, Sanger sequencing, and mass spectrometry. In this study, CYP2C19 and ABCB1 gene polymorphisms were for the first time detected using time-of-flight mass spectrometry (Clin-TOF) in Beijing district; Mass spectrometry, which is a soft-ionization technology that allows the analysis of biomolecules, has been reported to be a useful technology for the detection of SNPs ([@ref25]). Its advantages include the wide range of molecular weight that can be assuaged, the fast speed of scanning, the simple steps of operation, and particularly higher sequencing flux compared with that in Sanger sequencing. Mass spectrometry has a potential to become an applicable approach in clinical diagnosis and can be applied to genetic individualized therapy.

Study limitations {#sec2-12}
-----------------

This study has some limitations that need to be discussed. First, we excluded the differences between groups and ruled out the interaction of concurrent medications and coronary risk factors, but we did not exclude the possible bias of genetic polymorphisms, such as CYP3A4, CYP3A5, or other genetic variation involved in the reaction of P2Y12 inhibitors, that may influence the pharmacokinetics, pharmacodynamics, and clinical efficacy of clopidogrel. Second, the number of clopidogrel-treated patients was small, and we did not collect the follow-up the data of major adverse cardiovascular events (MACE) in these patients, which highlights the need for further researches to include a larger cohort and conduct a more complete follow-up data of study patients.

Conclusion {#sec1-5}
==========

In this study, we investigated the association between CYP2C19 and ABCB1 polymorphisms and CR in clopidogrel-treated Chinese patients. We observed that the carriage of CYP2C19\*2 or \*3 mutant allele was significantly associated with attenuated platelet response to clopidogrel and increased risk of CR, whereas the carriage of ABCB1 mutant allele was not significantly associated with the risk of CR. Our findings can provide an evidence for the early prediction of CR, guide the rational use of drugs, and reduce the incidence of adverse cardiovascular events in patients.
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